Jie Zhuye, Zhu Qian, Zou Yuanqiang, Wu Qili, Qin Min, He Dongdong, Lin Xiaoqian, Tong Xin, Zhang Jiahao, Jie Zhu, Luo Wenwei, Xiao Xiao, Chen Shiyu, Wu Yonglin, Guo Gongjie, Zheng Shufen, Li Yong, Lai Weihua, Yang Huanming, Wang Jian, Xiao Liang, Chen Jiyan, Zhang Tao, Kristiansen Karsten, Jia Huijue, Zhong Shilong
BGI-Shenzhen, Shenzhen, China.
Shenzhen Key Laboratory of Human Commensal Microorganisms and Health Research, BGI-Shenzhen, Shenzhen, China.
iScience. 2023 May 23;26(6):106960. doi: 10.1016/j.isci.2023.106960. eCollection 2023 Jun 16.
By a survey of metagenome-wide association studies (MWAS), we found a robust depletion of , , and in individuals with atherosclerotic cardiovascular disease (ACVD). From an established collection of bacteria isolated from healthy Chinese individuals, we selected , , and , a bacterium related to and tested the effects of these bacteria in an atherosclerosis mouse model. We show that administration of these three bacterial species to mice robustly improves cardiac function, reduces plasma lipid levels, and attenuates the formation of atherosclerotic plaques. Comprehensive analysis of gut microbiota, plasma metabolome, and liver transcriptome revealed that the beneficial effects are associated with a modulation of the gut microbiota linked to a 7α-dehydroxylation-lithocholic acid (LCA)-farnesoid X receptor (FXR) pathway. Our study provides insights into transcriptional and metabolic impact whereby specific bacteria may hold promises for prevention/treatment of ACVD.
通过对宏基因组全关联研究（MWAS）的调查，我们发现动脉粥样硬化性心血管疾病（ACVD）患者体内的[具体物种1]、[具体物种2]和[具体物种3]显著减少。从一组从健康中国个体分离出的既定细菌集合中，我们选择了[具体物种1]、[具体物种2]和[具体物种3]（一种与[相关物种]相关的细菌），并在ApoE−/−动脉粥样硬化小鼠模型中测试了这些细菌的作用。我们发现，给ApoE−/−小鼠施用这三种细菌可显著改善心脏功能、降低血浆脂质水平并减轻动脉粥样硬化斑块的形成。对肠道微生物群、血浆代谢组和肝脏转录组的综合分析表明，这些有益作用与肠道微生物群的调节有关，该调节与7α-脱羟基化-石胆酸（LCA）-法尼醇X受体（FXR）途径相关。我们的研究提供了关于转录和代谢影响的见解，即特定细菌可能为ACVD的预防/治疗带来希望。
